Literature DB >> 15350178

Blood pressure-lowering drugs: essential therapy for some patients with normal blood pressure.

Flávio D Fuchs1.   

Abstract

The risk of increasing blood pressure on the incidence of cardiovascular disease starts at 115/75 mmHg and roughly doubles for every 10 years increase in age, 20 mmHg increase in systolic blood pressure, 10 mmHg increase in diastolic blood pressure, or in the presence of comorbidities, such as diabetes or any evidence of cardiovascular disease. To lower blood pressure in patients with normal blood pressure and diabetes, or heart failure, or with any evidence of atherosclerotic disease in the coronary, cerebral and peripheral territories, reduces the incidence of major cardiovascular events by 18 to 42%. The diagnosis of hypertension in patients with these conditions is therefore irrelevant. The drugs that have mainly been tested in such conditions are the angiotensin-converting enzyme inhibitors, but their efficacy probably derives from their blood pressure-lowering effect, instead of a primary antiatherosclerotic effect.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15350178     DOI: 10.1586/14779072.2.5.771

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  3 in total

Review 1.  Blood pressure targets in the treatment of high blood pressure: a reappraisal of the J-shaped phenomenon.

Authors:  F D Fuchs; S C Fuchs
Journal:  J Hum Hypertens       Date:  2013-08-22       Impact factor: 3.012

2.  Prevention of hypertension in patients with pre-hypertension: protocol for the PREVER-prevention trial.

Authors:  Flávio D Fuchs; Sandra C Fuchs; Leila B Moreira; Miguel Gus; Antônio C Nóbrega; Carlos E Poli-de-Figueiredo; Décio Mion; Luiz Bortoloto; Fernanda Consolim-Colombo; Fernando Nobre; Eduardo Barbosa Coelho; José F Vilela-Martin; Heitor Moreno; Evandro José Cesarino; Roberto Franco; Andréa Araujo Brandão; Marcos R de Sousa; Antônio Luiz Pinho Ribeiro; Paulo Cesar Jardim; Abrahão Afiune Neto; Luiz César N Scala; Marco Mota; Hilton Chaves; João Guilherme Alves; Dario C Sobral Filho; Ricardo Pereira e Silva; José A Figueiredo Neto; Maria Cláudia Irigoyen; Iran Castro; André Avelino Steffens; Rosane Schlatter; Renato Bandeira de Mello; Francisca Mosele; Flávia Ghizzoni; Otávio Berwanger
Journal:  Trials       Date:  2011-03-05       Impact factor: 2.279

Review 3.  Preventing the progression of prehypertension to hypertension: role of antihypertensives.

Authors:  Flávio Danni Fuchs; Renato Bandeira de Mello; Sandra Costa Fuchs
Journal:  Curr Hypertens Rep       Date:  2015-01       Impact factor: 5.369

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.